Rituximab maintenance therapy in indolent NHL: a clinical review

被引：10

作者：

Buske, C ^{[1
]}

Hiddemann, W ^{[1
]}

机构：

[1] Univ Munich, Klinikum Grosshadern, Med Klin 3, D-81377 Munich, Germany

来源：

LEUKEMIA RESEARCH | 2006年 / 30卷

关键词：

rituximab; maintenance therapy; follicular lymphoma; immunochemotherapy;

D O I：

10.1016/S0145-2126(06)80003-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Rituximab maintenance therapy following successful induction has emerged as a highly effective treatment for follicular lymphoma. Several randomized trials have been conducted analyzing the impact of rituximab maintenance compared to observation alone on treatment outcome. These studies have been conducted in patients receiving single-agent rituximab, standard chemotherapy or rituximab plus chemotherapy as initial cytoreduction, in both previously treated and untreated patients. In all the trials, rituximab maintenance resulted in a clinically and statistically significant benefit in clinical endpoints such as progression-free survival. Moreover, first data indicate that rituximab maintenance can prolong overall survival in patients with follicular lymphoma. These data have established rituximab maintanance as an important part of multimodal therapeutic strategies. Ongoing studies will help to determine the best schedule for the maintenance therapy in the treatment of follicular lymphoma. (C) 2006 Elsevier Ltd. All rights reserved.

引用

页码：S11 / S15

页数：5

共 19 条

[1]

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[2]

DREYLING M, 2005, P AN M AM SOC CLIN, pS567

[3]

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Forstpointner, R ;

Dreyling, M ;

Repp, R ;

Hermann, S ;

Hänel, A ;

Metzner, B ;

Pott, C ;

Hartmann, F ;

Rothmann, F ;

Rohrberg, R ;

Böck, HP ;

Wandt, H ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2004, 104 (10) :3064-3071

[4]

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule [J].

Ghielmini, M ;

Schmitz, SFH ;

Cogliatti, SB ;

Pichert, G ;

Hummerjohann, J ;

Waltzer, U ;

Fey, MF ;

Betticher, DC ;

Martinelli, G ;

Peccatori, F ;

Hess, U ;

Zucca, E ;

Stupp, R ;

Kovacsovics, T ;

Helg, C ;

Lohri, A ;

Bargetzi, M ;

Vorobiof, D ;

Cerny, T .

BLOOD, 2004, 103 (12) :4416-4423

[5]

Hagenbeek A, 2005, ANN ONCOL, V16, P52

[6]

Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the minnie pearl cancer research network [J].

Hainsworth, JD ;

Litchy, S ;

Shaffer, DW ;

Lackey, VL ;

Grimaldi, M ;

Greco, EA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1088-1095

[7]

Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma [J].

Hainsworth, JD ;

Litchy, S ;

Burris, HA ;

Scullin, DC ;

Corso, SW ;

Yardley, DA ;

Morrissey, L ;

Greco, FA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4261-4267

[8]

Herold M, 2005, ANN ONCOL, V16, P51

[9]

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[10]

HIDDEMANN W, 2005, P AN M AM SOC CLIN, V23, pS566

← 1 2 →